EQT agrees €9.6bn deal for molecular testing firm Qiagen

· Health · Germany · Sweden

Swedish private equity group EQT AB agreed to acquire Qiagen NV, a European molecular testing company, for around €9.6 billion ($10.8 billion), ending years of takeover speculation. The deal would take one of Europe's better-known diagnostics firms private amid consolidation in the life-sciences tools sector. Qiagen's tests are used in research and clinical diagnostics, and the acquisition adds to a wave of large healthcare buyouts by private capital.

Why it matters：The buyout shows private equity's appetite for diagnostics assets and could reshape competition in Europe's life-sciences supply chain.

Key points

  • EQT will pay about €9.6bn ($10.8bn).
  • Qiagen is a European molecular testing firm.
  • The deal ends years of takeover speculation.

Sources (original reporting)

More stories from this day